SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Innocoll Holdings plc, and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm

IRVINE, CA / ACCESSWIRE / March 21, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Innocoll Holdings plc (“Innocoll” or the “Company”) (NASDAQ: INNL). Investors, who purchased or otherwise acquired Innocoll shares between November 3, 2016 through December 29, 2016, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.

If you purchased shares of Innocoll during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

XARACOLL is Innocoll’s lead product candidate. Innocoll issued a New Drug Application (“NDA”) under the U.S. Food & Drug Administration (“FDA”) in October 2016. On December 29, 2016, Innocoll announced that it had received a Refusal to File letter from the FDA as to XARACOLL’s NDA. According to Innocoll, the FDA stated that XARACOLL should be considered a drug/device combination and asked Innocoll to submit further information.

When this information was released to the public, the value of Innocoll stock fell up to 66%, causing investors serious harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457839